1. Dementia care is reaching emergency levels as baby boomers age. 2. Projected dementia cases will double by 2060, stressing healthcare resources. 3. There is a critical shortage of dementia specialists and neurologists. 4. Telehealth is emerging as a necessary solution for dementia care. 5. 90% of mild cognitive impairment patients remain undiagnosed, limiting treatment.
Despite the ongoing challenges, the increasing demand for dementia treatments like BIIB's Leqembi may boost its market potential, similar to Eli Lilly's growth post FDA approval of donanemab.
The article highlights critical issues in dementia care that can drive demand for BIIB's products, indicating potential for substantial revenue growth as market needs evolve.
With dementia cases projected to rise significantly, the demand for treatments like Leqembi will likely sustain growth over the long term, paralleling how increased demand for Alzheimer’s treatments has influenced stock prices historically.